Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Am J Transplant ; 20(2): 593-599, 2020 02.
Artigo em Inglês | MEDLINE | ID: mdl-31400258

RESUMO

Antibody-mediated rejection (AMR) in heart transplants in the absence of anti-HLA donor-specific antibody (DSA) is not well studied or documented. This case reviews hyperacute fulminant graft dysfunction suspected to be mediated by non-HLA antibodies. After cross clamp removal, the patient developed severe pulmonary edema, profound coagulopathy, and biventricular failure. The patient's presumed AMR, cardiogenic shock, and coagulopathy were treated with extracorporeal membrane oxygenation (ECMO), plasmapheresis, intravenous immunoglobulin (IVIG), multiple blood products, and prothrombin complex concentrate. The recipient was 0% panel-reactive antibody (PRA), ABO, and crossmatch compatible. Intraoperative biopsy sample revealed a thrombotic process suggestive of a coagulation pathway activated by AMR; however, no C4d deposition was detected. Postmortem biopsies also suggested AMR. Retrospective testing of the patient's pretransplant serum revealed strong antiangiotensin II type 1 receptor (AT1R) antibodies and a strongly positive endothelial cell crossmatch. Anti-AT1R antibodies are known to be AT1 receptor agonists and may trigger inflammation and activate the extrinsic coagulation pathway. Given the potential effects of signaling through the AT1R, the patient's preexisting anti-AT1R antibodies and procoagulant therapy may have adversely affected the patient's clinical course.


Assuntos
Rejeição de Enxerto/etiologia , Transplante de Coração , Receptor Tipo 1 de Angiotensina/agonistas , Adulto , Idoso , Tipagem e Reações Cruzadas Sanguíneas , Oxigenação por Membrana Extracorpórea , Rejeição de Enxerto/imunologia , Antígenos HLA/imunologia , Teste de Histocompatibilidade , Humanos , Masculino , Disfunção Primária do Enxerto/etiologia , Receptor Tipo 1 de Angiotensina/imunologia
2.
Transfusion ; 60(3): 488-497, 2020 03.
Artigo em Inglês | MEDLINE | ID: mdl-31951028

RESUMO

BACKGROUND: Single antigen bead (SAB) assays are used to identify human leukocyte antigen (HLA) antibodies in patients with platelet refractoriness due to HLA Class I alloimmunization. Some laboratories use serum pretreatment regimens to eliminate interference from immunoglobulin M antibodies and complement. These modifications may contribute to interlaboratory variability, which is a recognized problem with the SAB assay. STUDY DESIGN AND METHODS: Five patients' sera were overnight shipped to 12 laboratories in the United States and internationally. Recipients used their lab's SAB procedure to identify HLA Class I antibodies. The resultant mean fluorescence intensity (MFI) data were compared by instrumentation, bead lot, and pretreatment regimens. Laboratory-specific cutoffs for positive antibodies were applied to the results. RESULTS: Interlaboratory variability for MFI values appears to be associated with different pretreatment regimens. The coefficient of variation (CV) of MFI from samples pretreated with ethylenediaminetetraacetic acid, dithiothreitol, or heat inactivation (EDHI) were similar, ranging from 14% to 56% (mean, 22%). For samples with no pretreatment, the CVs were significantly higher than EDHI-treated samples, ranging from 25% to 74% (mean, 39%; 95% confidence interval, 12.10-21.90; p < 0.0001). An intralaboratory comparison of pretreatment regimens confirmed these findings. Some positive antibody specificities present in EDHI-treated samples were negative in corresponding samples with no pretreatment when laboratory-specific cutoffs for positive antibodies were applied. CONCLUSION: Our results show that greater interlaboratory precision can be achieved when samples are pretreated with EDHI as opposed to no pretreatment, likely because these pretreatments eliminate interference from inhibitors. Inhibitors may mask antibodies, leading to missed (or uncalled) specificities when no pretreatment is used.


Assuntos
Antígenos de Histocompatibilidade Classe I/imunologia , Isoanticorpos/imunologia , Especificidade de Anticorpos , Plaquetas/efeitos dos fármacos , Plaquetas/metabolismo , Ditiotreitol/farmacologia , Ácido Edético/farmacologia , Feminino , Antígenos HLA/metabolismo , Teste de Histocompatibilidade , Humanos , Imunoglobulina M/metabolismo , Masculino
3.
Transplantation ; 87(4): 557-62, 2009 Feb 27.
Artigo em Inglês | MEDLINE | ID: mdl-19307794

RESUMO

BACKGROUND: The requirement for a prospective crossmatch limits some organ allocation to local areas. The delay necessitated by the crossmatch restricts the distance across which offers can be made without unduly increasing the ischemia time. A collaborative study involving 14 transplant centers was undertaken by the Organ Procurement and Transplantation Network/United Network for Organ Sharing (OPTN/UNOS) Histocompatibility Committee to evaluate the accuracy with which the detection of unacceptable human leukocyte antigen (HLA) antigens by most advanced solid phase immunoassays can predict crossmatch results. In addition, using actual patients' unacceptable HLA antigens, the number of compatible donors that would have been available from the OPTN deceased kidney donors during 2002 to 2004 were investigated. METHODS: Panel reactive antibodies were performed by conventional or solid phase assays, and crossmatches were performed by cytotoxicity or flow cytometry. Analyses were stratified for T and B cell and by method of identifying unacceptable HLA antigens and crossmatch techniques. RESULTS: Combination of solid phase immunoassays and flow cytometry crossmatches resulted in a higher prediction rates of positive T cell (86.1%-93.5%) and B-cell crossmatches (91%-97.8%). Prediction of negative crossmatches based on different combination of panel reactive antibodies and crossmatch techniques varied from 14.3% to 57.1%. Furthermore, numerous potential compatible donors were identified for each patient, regardless of their ethnicity, in the OPTN database, when predicted incompatible ones were excluded. CONCLUSIONS: The above results showed that with the advent of solid phase immunoassays, HLA antibodies can now be accurately detected resulting in prediction of crossmatch outcome. This should facilitate organ allocation and prevents shipment of organs to distant incompatible recipients.


Assuntos
Linfócitos B/imunologia , Teste de Histocompatibilidade/métodos , Linfócitos T/imunologia , Doadores de Tecidos/estatística & dados numéricos , Obtenção de Tecidos e Órgãos/métodos , Ensaio de Imunoadsorção Enzimática , Citometria de Fluxo , Antígenos HLA/imunologia , Histocompatibilidade/imunologia , Humanos , Isoanticorpos/sangue , Valor Preditivo dos Testes , Obtenção de Tecidos e Órgãos/estatística & dados numéricos
4.
Pediatr Dev Pathol ; 5(2): 200-5, 2002.
Artigo em Inglês | MEDLINE | ID: mdl-11910516

RESUMO

Severe neonatal thrombocytopenia is associated with a significant risk of neonatal bleeding complications. It may result from increased consumption, increased destruction, deficient production, or abnormal sequestration within the spleen. When immune mediated, most cases of clinically significant neonatal thrombocytopenia are due to maternal alloimmunization to paternally derived platelet antigens present on fetal platelets. We present the clinical, placental, and immunohematologic findings of a case of severe neonatal alloimmune thrombocytopenia (NAITP) complicated by additional HLA group alloimmunization. The placenta showed chronic villitis of unknown etiology (VUE) and diffuse microthrombi within the villous capillaries, indicating that abnormal thrombogenesis can be a complication of severe NAITP.


Assuntos
Plaquetas/imunologia , Antígenos HLA/imunologia , Doenças do Recém-Nascido/imunologia , Doenças Placentárias/etiologia , Trombocitopenia/imunologia , Adulto , Tipagem e Reações Cruzadas Sanguíneas , Plaquetas/patologia , Vilosidades Coriônicas/irrigação sanguínea , Vilosidades Coriônicas/patologia , Feminino , Humanos , Recém-Nascido , Doenças do Recém-Nascido/patologia , Isoanticorpos/análise , Doenças Placentárias/patologia , Gravidez , Trombocitopenia/patologia , Vasculite/etiologia , Vasculite/patologia
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa